Intellectual property rules and market access conditions remain a sticking point for foreign drug makers in Thailand.
Active clinical trials in the country fell to 510 in 2025. Thailand is lining up billions in pharmaceutical investment, but patent delays, pricing controls and a shrinking clinical trial base threaten to limit what the money delivers. According to a BMI report, the Ministry of Public Health (MoPH) signed an agreement with Merck Sharp & Dohme (MSD) Thailand on 9 September under the Medical Investment Hub initiative.
This aims to make healthcare a key growth source through 2034 and generate economic value equivalent to at least 0.5% of GDP. Roche has signalled plans to invest $450m (THB15b) in…
Read the full report on Healthcare Asia Magazine
Story file
- Section
- Health
- Topics
- Economy & RBI, Health alerts
- First reported by
- Healthcare Asia Magazine
- Reporter
- staff reporter
- Published
- Tuesday, 13 October 2026, 2:30 am IST
- Coverage
- One outlet so far
How this page works. The Headline Update lists this report from Healthcare Asia Magazine with a short summary and a link to the original. The original reporting and photograph belong to the publisher. Spotted an error in our summary? Tell our corrections desk.
